Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 3:13 AM ET


Company Overview of Alvogen, Inc.

Company Overview

Alvogen, Inc. engages in the product development, contract manufacturing and research, and sale of generic and brand medicines, biosimilars, and OTC products. Its product portfolio comprises a range of molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology, and gastroenterology. The company focuses on niche generics, patches, controlled release, and narcotics in the form of solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables; promotes and distributes various biosimilar products for indications across several therapeutic areas; provides contract manufacturing, product development, ...

10 Bloomfield Avenue

Pine Brook, NJ 07058

United States

Founded in 2008





Key Executives for Alvogen, Inc.

Executive Chairman and Chief Executive Officer
Executive Vice President of Global Supply Chain
Chief Operating Officer and Member of Executive Board
Member of Executive Board and Chief Executive Officer of Alvogen America
Age: 45
President of Alvogen America
Compensation as of Fiscal Year 2015.

Alvogen, Inc. Key Developments

Alvogen, Inc. Announces Executive Changes

Alvogen announced that Kevin Bain, the company‘s Chief Financial Officer since 2009 will take on the role of Chief Financial Officer of Alvogen‘s biotech sister company, Alvotech and continue as EVP of Strategic Development at Alvogen. Alvogen also announced that Graham Baker will be appointed as the group‘s new Chief Financial Officer, effective 1 November 2015. Graham joins Alvogen from AstraZeneca, where he has spent the past 20 years of his career, most recently as Vice President of Finance for AstraZeneca’s international business. Graham will be responsible for all global finance and information services for Alvogen.

Alvogen Launches the First Generic Exelon® Patch in the United States

Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal system) in the United States. The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the 13.3 mg/24 hours strength, making it eligible for 180 days of marketing exclusivity. Novartis’s Exelon® patch, delivered sales of approximately $400 million in the United States during 2014.

Alvogen Appoints Lisa Graver as President of Americas Region

Alvogen announced the appointment of Lisa Graver as president of Americas region effective immediately.

Similar Private Companies By Industry

Company Name Region
PreventAGE Health Care, LLC United States
Samumed, LLC United States
Convoy Therapeutics, Inc. United States
The GID Group, Inc. United States
Cypress Systems, Inc. United States

Recent Private Companies Transactions

August 24, 2015
Pfizer Inc., Four Pharmaceutical Products
June 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alvogen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at